Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2) [Phase 3]

View source ↗

Summary

Phase 3 trial EXPEDITION-2 evaluated ABT-493/ABT-530 for efficacy and safety in adults with chronic hepatitis C virus genotype 1-6 infection and HIV coinfection…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C
• Human Immunodeficiency Virus Infection

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-05-09